

DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Infectious Disease – Livtency Drug Quantity Management Policy – Per Days

- Livtency™ (maribavir tablets – Takeda)

REVIEW DATE: 12/07/2022

OVERVIEW

Indication

Livtency, an antiviral, is indicated for the treatment of adult and pediatric patients (≥ 12 years of age and weighing ≥ 35 kg) with **post-transplant cytomegalovirus (CMV) infection/disease** that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet.¹

Dosing

The recommended dose of Livtency is 400 mg (two 200 mg tablets) taken twice daily (BID) with or without food.¹ The dose of Livtency should be increased to 800 mg BID in patients who are also taking carbamazepine; and to 1,200 mg BID in patients who are also taking phenytoin or phenobarbital. In pivotal studies, Livtency was used for up to 8 weeks.

Availability

Livtency is available as 200 mg tablets, in bottles of 28 or 56 tablets.¹

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Livtency. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 8 weeks, unless otherwise noted below.

Automation: None.

Drug Quantity Limit

Product	Strength	Retail Maximum Quantity per 28 Days	Home Delivery Maximum Quantity per 56 Days
Livtency™ (maribavir tablets)	200 mg tablets	112 tablets*	224 tablets*

*This is enough drug to allow for two 200 mg tablets twice daily for 28 days at retail or 56 days at home delivery.

12/07/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

CRITERIA

1. If a patient is taking carbamazepine concomitantly with Livtencity, approve 224 tablets per 28 days for up to 8 weeks (56 days) at retail or a one-time override for 448 tablets as a 56-day supply at home delivery.
2. If a patient is taking phenytoin or phenobarbital concomitantly with Livtencity, approve 336 tablets per 28 days for up to 8 weeks (56 days) at retail or a one-time override for 672 tablets as 56-day supply at home delivery.

REFERENCES

1. Livtencity™ tablets [prescribing information]. Lexington, MA: Takeda: September 2022.